文献速递慢性肾脏病

尿酸与慢性肾脏病:仍有大量工作待完成

Uric Acid and Chronic Kidney Disease: Still More to Do.
PubMed 文献 · Kidney Int Rep · 2022-12-05

综述探讨尿酸在慢性肾脏病进展和代谢并发症中的作用争议。慢性肾脏病患者中痛风和高尿酸血症分别占25%和60%。证据总体提示无症状高尿酸血症可能有害,但主要与特定亚组相关;作者建议精心设计临床试验验证降尿酸是否具有保护作用。

要点

  • 慢性肾脏病患者中痛风占25%,高尿酸血症占60%。
  • 无症状高尿酸血症可能有害,但主要与全身晶体沉积、反复尿结晶或肾结石、高细胞内尿酸水平亚组相关。
  • 作者建议精心设计临床试验验证伴心脏代谢并发症的高尿酸血症患者降尿酸是否具有保护作用。

核心结论

  • 证据总体提示无症状高尿酸血症可能有害,但可能主要与全身晶体沉积、频繁尿结晶或肾结石、高细胞内尿酸水平亚组相关。
  • 作者建议精心设计临床试验验证伴心脏代谢并发症的高尿酸血症患者降尿酸是否具有保护作用。

研究设计与样本

  • 综述,回顾支持与反对治疗高尿酸血症的各种论据。

主要发现

  • 慢性肾脏病患者中痛风占25%,高尿酸血症占60%。
  • 部分权威认为慢性肾脏病无症状高尿酸血症无需治疗,部分甚至提出高尿酸血症可能有益。
  • 证据总体提示无症状高尿酸血症可能有害,但可能主要与特定亚组相关。

临床怎么用

  • 作者建议精心设计临床试验验证伴心脏代谢并发症的高尿酸血症患者降尿酸是否具有保护作用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gout and hyperuricemia are present in 25% and 60% of patients with chronic kidney disease (CKD), respectively. Despite the common association, the role of uric acid in the progression of kidney disease and in metabolic complications remains contested. Some authorities argue that the treatment of asymptomatic hyperuricemia in CKD is not indicated, and some have even suggested hyperuricemia may be beneficial. Here, we review the various arguments both for and against treatment. The weight of the evidence suggests asymptomatic hyperuricemia is likely injurious, but it may primarily relate to subgroups, those who have systemic crystal deposits, those with frequent urinary crystalluria or kidney stones, and those with high intracellular uric acid levels. We recommend carefully designed clinical trials to test if lowering uric acid in hyperuricemic subjects with cardiometabolic complications is protective.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Johnson RJ, Sanchez Lozada LG, Lanaspa MA, et al. Uric Acid and Chronic Kidney Disease: Still More to Do. Kidney Int Rep. 2022. PMID: 36815099. doi:10.1016/j.ekir.2022.11.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。